These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 1543948

  • 21. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, de Witte T.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [Abstract] [Full Text] [Related]

  • 22. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 23. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
    Blaise D, Gaspard MH, Stoppa AM, Michel G, Gastaut JA, Lepeu G, Tubiana N, Blanc AP, Rossi JF, Novakovitch G.
    Bone Marrow Transplant; 1990 Jan 20; 5(1):7-12. PubMed ID: 2404531
    [Abstract] [Full Text] [Related]

  • 24. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar 20; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 25. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 20; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May 20; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide.
    Angelucci E, Polchi P, Lucarelli G, Galimberti M, Baronciani D, Giardini C, Durazzi SM, Moretti L, Donati M.
    Haematologica; 1989 May 20; 74(5):455-61. PubMed ID: 2511115
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
    Vey N, De Prijck B, Faucher C, Stoppa AM, Sainty D, Lafage M, Bouabdallah R, Chabannon C, Camerlo J, Gastaut JA, Maraninchi D, Blaise D.
    Bone Marrow Transplant; 1996 Sep 20; 18(3):495-9. PubMed ID: 8879608
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
    Glejzer O, Sedzimirska M, Tomaszewska-Toporska B, Tomeczko J, Kołodziej J, Pacuszko T, Was A, Bocheńska J, Jaźwiec B, Klimczak A.
    Acta Haematol Pol; 1992 Sep 20; 23(2 Suppl 1):49-59. PubMed ID: 1488872
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.